Navigation Links
Venaxis Announces Pricing of Offering of Common Stock and Warrants
Date:5/23/2013

ase that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 test required for FDA submission, obtain FDA clearance or approval, maintain CE marking, cost effectively manufacture and generate revenues from the APPY1 test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including the Form S-1/A registration statement filed on May 23, 2013.

 


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
2. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment
3. PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits
4. Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
5. Emerson Resources Announces CEO Retirement and Appointment of Successor
6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
7. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
8. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
9. SoundConnect Announces Microsoft Lync Release in Canada
10. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
11. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... GenoCAD , a platform leveraging the ... announced the formation of its new board of advisors ... a broad range of experience in the biotechnology, pharmaceutical, ... , Jimmy Roussel, Entrepreneur in Residence at The New ... technology and marketing. He has served in operations roles ...
(Date:6/1/2015)... 2015 Research and ... addition of the "Oxidative Stress Assay ... Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769) , The global oxidative ...
(Date:6/1/2015)... GenomeDx Biosciences today announced that ... classified various subtypes of bladder cancer based ... including one type associated with resistance to ... has potential as a tool to predict ... with muscle-invasive bladder cancers (MIBC). The study ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
Breaking Biology Technology:GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... 20 At a meeting of the Board,of Directors of ... of fifty cents($0.50) per share on the outstanding shares of ... of record at the close of business,on December 12, 2008. ... of the world,s largest research-driven pharmaceutical and,health care products companies. ...
... 20 Sigma-Aldrich (Nasdaq: SIAL ),announced today ... iScale,Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) ... next step in their RNAi,research with the highest purity ... These siRNA are believed to be well suited to ...
... Nephros, Inc. (Amex: NEP ), a medical device company developing and marketing ... on its operations and strategy. , , Recent ... , Appointed James Scibetta Chairman of ... III President and CEO , Submitted 510k for ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... a class of small molecules known as microRNA have been ... in most animal and plant species. A new study now ... a hallmark of alcohol abuse and dependence. Researchers supported by ... the findings in the July 31 issue of the journal ...
... July 29, 2008 Two Fortune 500 oil companies ... Engineering at the University of Houston. The funds, from ... Corp., will provide support for a new undergraduate program ... by the Texas Higher Education Coordinating Board this fall. ...
... or cold is not only uncomfortable, it can be ... many years now, scientists have understood the molecular mechanisms ... extremely high temperatures that directly trigger heat sensor proteins ... understood is how animals sense very small temperature differences ...
Cached Biology News:MicroRNA implicated as molecular factor in alcohol tolerance 2Energy industry leaders commit $1.6M to UH petroleum program 2Energy industry leaders commit $1.6M to UH petroleum program 3Summer heat too hot for you? What is comfortable? 2Summer heat too hot for you? What is comfortable? 3